The recent announcement by President Donald Trump to impose a 25% tariff on imports from Mexico and Canada is poised to significantly affect the U.S. healthcare sector, particularly hospitals and health systems. These tariffs, that took effect on March 4, 2025, aim to address concerns over illegal immigration and drug trafficking but carry substantial implications for medical supply chains, hospital profitability and patients..
The United States heavily relies on imports from Mexico and Canada for various medical instruments and supplies and both countries are top suppliers of these goods to the United States. In 2024, the U.S. imported approximately $5.34 billion in medical supplies and pharmaceutical products from Canada. From Mexico in that same time period, the U.S. imported $509.96 billion in medical supplies and pharmaceutical products. (This doesn’t include durable medical equipment, diagnostic machinery, or surgical equipment.) President Trump’s tariffs will add $128.825 billion to that cost.
The imposition of a 25% tariff on these critical imports is expected to escalate costs for hospitals and health systems. A survey of industry professionals revealed that over 80% anticipate at least a 15% surge in expenses for hospitals and health systems within the next six months due to increased import costs. Such financial pressures could lead to higher patient fees, reduced staffing, or deferred investments in critical infrastructure. This financial strain may lead to higher operational costs, potentially resulting in increased healthcare expenses for patients.
Importantly, the tariffs could disrupt the availability of essential medical equipment. Medical device manufacturers, such as Medtronic, are assessing their global manufacturing operations in response to the proposed tariffs, indicating potential supply chain adjustments that could affect product availability. Such disruptions may hinder hospitals’ ability to provide timely and effective care.
These proposed tariffs would be a disruptive force on a healthcare supply chain that has finally come out of the COVID-19 pandemic and gotten back to a “new normal” of tighter margins.